Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab

NCT02600169 · clinicaltrials.gov ↗

COMPLETED

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Pemprolizumab

Sponsor

University Medical Center Groningen